drugset / Trial / NCT03850769
Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study was a single-arm multicenter prospective phase II clinical study, designed to evaluate the efficacy and safety of neoadjuvant nab-paclitaxel combined with S-1 in patients with borderline resectable pancreatic cancer. A total of 60 subjects who meet the criteria will receive neoadjuvant chemotherapy of nab-paclitaxel and S-1, for a maximum of 4 cycles prior to pancreatectomy. The primary endpoint is R0 resection rate, the secondary endpoints include overall survival and response rate.
Timeline
- Start
- 2019-05-01
- Primary completion
- 2022-03
- Completion
- 2022-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nab-paclitaxel | Small molecule | 120 mg/m2 | — |
| Subject | S-1 | Small molecule | 80 mg | — |
| Subject | S-1 | Small molecule | 100 mg | — |
| Subject | S-1 | Small molecule | 120 mg | — |